+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biosimilars: Access & Reimbursement - Rest of World

  • ID: 4705801
  • Report
  • May 2018
  • Region: Global
  • 78 pages
  • Decision Resources Group
1 of 3

FEATURED COMPANIES

  • amgen
  • Celltrion
  • Eli Lilly
  • Eurofarma
  • Libbs Farmacêutica
  • Mochida
  • MORE
This Biosimilars Access & Reimbursement report for rest of the world(Japan, Australia, Brazil, Canada, China, India, Mexico, Russia, South Korea), provides brand-level insight regarding the impact of payer policy on physician prescribing behavior in Japan, Australia, Brazil, Canada, China, India, Mexico, Russia, South Korea Biosimilars market so you can optimize your market access strategy and determine how to best position your biosimilar to specific stakeholders.

This report includes specific detail on the Biosimilars market access trends in Japan, Australia, Brazil, Canada, China, India, Mexico, Russia, South Korea, insight on how to maximize opportunity and limit barriers, analysis of key reimbursement decision-makers and the criteria they use, review of market access strategies used by competitors and highlights of where they succeeded or stumbled, detailed analysis of physician and payer perceptions based on physician surveys in-depth interviews with payers, and much more. This report is most relevant for professionals in market research, business intelligence, market access, brand teams, launch planning teams, business development & licensing. This report was published in May 2018.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • amgen
  • Celltrion
  • Eli Lilly
  • Eurofarma
  • Libbs Farmacêutica
  • Mochida
  • MORE
Japan
1. Key Findings
2. Regulations and Guidance

Australia
1. Key Findings
2. Regulations and Guidance

Brazil
1. Key Findings
2. Regulations and Guidance

Canada
1. Key Findings
2. Regulations and Guidance

China
1. Key Findings
2. Regulations and Guidance

India
1. Key Findings
2. Regulations and Guidance

Mexico
1. Key Findings
2. Regulations and Guidance

Russia
1. Key Findings
2. Regulations and Guidance

South Korea
1. Key Findings
2. Regulations and Guidance
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Eurofarma
  • Libbs Farmacêutica
  • Pfizer
  • amgen
  • Teva
  • Celltrion
  • Eli Lilly
  • Mochida
  • Sandoz/Nipro
Note: Product cover images may vary from those shown
Adroll
adroll